AKARNA THERAPEUTICS

Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.